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ORIGINAL ARTICLE
Immediate postoperative high-sensitivity troponin
T concentrations and long-term patient-reported
health-related quality of life
A prospective cohort study
Kristin H.J.M. Mol, Felix van Lier, Victor G.B. Liem, Robert J. Stolker and Sanne E. Hoeks
BACKGROUND Myocardial injury after noncardiac surgery
is associated with mortality and major adverse postoperative
cardiovascular events. The effect of postoperative troponin
concentrations on patient-reported health-related quality of
life (HRQoL) is unknown.
OBJECTIVE The study examined the association between
immediate postoperative troponin concentrations and self-
reported HRQoL 1 year after surgery.
DESIGN Prospective cohort study.
SETTING Single-centre tertiary care hospital in the
Netherlands between July 2012 and 2015.
PATIENTS Patients aged at least 60 years undergoing
moderate and major noncardiac surgery.
INTERVENTION None.
MAIN OUTCOME MEASURES HRQoL total score was
assessed with the EuroQol five-dimensional questionnaire.
Tobit regression analysis was used to determine the associ-
ation between postoperative troponin concentrations and
1-year HRQoL. Peak high-sensitivity troponin T values were
divided into four categories: less than 14, 14 to 49, 50 to 149
and at least 150 ng l1.
RESULTS A total of 3085 patients with troponin measure-
ments were included. 2634 (85.4%) patients were alive at 1-
year follow-up of whom 1297 (49.2%) returned a completed
questionnaire. The median score for HRQoL was 0.82 (0.85,
0.81, 0.77 and 0.71 per increasing troponin category).
Multivariable analysis revealed betas of 0.06 [95% confi-
dence interval (CI) 0.09 to 0.02], 0.11 (95% CI 0.18
to 0.04) and 0.18 (95% CI 0.29 to 0.07) for troponin
levels of 14 to 49, 50 to 149 and at least 150ng l1 when
compared with values less than 14ng l1. Other indepen-
dent predictors for lower HRQoL were chronic obstructive
pulmonary disease, female sex, peripheral arterial disease
and increasing age.
CONCLUSION Higher levels of postoperative troponin mea-
sured immediately after surgery were independently associ-
ated with lower self-reported HRQoL total score at 1-year
follow-up.
Published online 29 June 2020
Introduction
A substantial number of patients undergoing intermedi-
ate to high-risk noncardiac surgery develop peri-opera-
tive myocardial injury,1–3 detected by an elevated
troponin level.4 Postsurgical troponin concentrations
have been shown to be independently associated with
early and late mortality and also major adverse cardiovas-
cular events (MACE).1,2,5,6
Physical wellbeing following surgery is traditionally eval-
uated by using clinical measures such as surgical outcome
and mortality, but patient-reported outcome measures
(PROMs) are increasingly being regarded as important.7
Health-related quality of life (HRQoL) is such a PROM,
measuring the impact of disease on physical and mental
health. The EuroQol questionnaire is a worldwide, vali-
dated tool to assess this nondisease-specific health sta-
tus.8,9 It is mostly used within diseases to assess
treatment effect, but if used as a generic measure, it
holds the promise to be a generalised measurable
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outcome for patients with different diseases. Adverse
cardiovascular outcomes are known to affect quality of
life and vice versa.10 Moreover, cardiac biomarkers are
independently associated with deterioration of quality of
life in nonsurgical patients.14,15 The relationship
between postsurgical troponin concentrations and
adverse clinical outcome is well known, but its relation
with HRQoL has not been evaluated before. Extending
previous findings of troponin measurements with
PROMs can further emphasise their clinical value and
could help guide the allocation of healthcare resources. In
this study, we assess the relationship between postoper-
ative troponin release and HRQoL at 1-year follow-up
after intermediate to high-risk noncardiac surgery.
Methods
Study design, setting and participants
The current study is nested within an observational cohort
registry of patients aged at least 60 years undergoing
intermediate-to-high risk noncardiac surgery at the Eras-
mus University Medical Centre, Rotterdam, the
Netherlands between July 2012 and July 2015, who have
been described previously.1,11,12 This registry was
reviewed by the Medical Ethical Committee of Erasmus
University, Rotterdam, who approved the noninterven-
tional character of the study (MEC-2013-397). The study
was conducted in compliance with the Helsinki declara-
tion13 and strengthening the reporting of observational
studies in epidemiology criteria14 for observational studies.
Troponin measurements were routinely obtained on
postoperative days 1, 2 and 3, unless discharged earlier.
Previous medical history and clinical characteristics were
collected retrospectively from medical records. Informa-
tion on MACE and HRQoL was obtained 1 year after
surgery by sending out written questionnaires. Data on
quality of life were not available for patients who did not
respond or died within the first year and consequently,
these patients were not included in the final analysis.
Endpoints and measurements
Postoperative troponin measurements
Troponin measurement on the first 3 days after surgery is
standard clinical care in patients aged 60 years and older
undergoing intermediate-to-high risk noncardiac surgery
at the Erasmus University Medical Centre. The Roche
fifth-generation Elecsys high-sensitivity troponin T assay
is used. For analysis, troponin levels were divided into
four categories, as previously published.1,11,12 The first
category (<14 ng l1) is considered normal, based on the
manufacturer’s 99th percentile of a normal population.15
The second (14 to 49 ng l1) was based on the
0.03 ng ml1 threshold of the fourth-generation assay’s
abnormal elevations, which is equivalent to 50 ng l1 of
the fifth assay.16 The highest threshold was extrapolated
from the highest threshold in the Vascular events In
noncardiac Surgery patIents cOhort evaluatioN study,2
which was 10 times the threshold of an abnormal troponin
elevation, that is 140 ng l1 for the fifth generation, round-
ing off to 150 ng l1.
Troponin concentrations at least 50 ng l1 were evaluated
for meeting the diagnostic criteria of the third universal
definition of postoperative myocardial infarction (MI).4
Questionnaires
Follow-up data for MACE and quality of life were
acquired 1 year after the date of surgery, either through
questionnaires sent out by postal mail or, in case of a
nonresponse, by telephone interview. The question-
naires consisted of a structured investigation of the
patients’ own report on MACE1 combined with the
EuroQol five-dimensional questionnaire (EQ-5D-5L)
to assess present health status and HRQoL. For MACE,
all patient-reported events were checked in the elec-
tronic hospital patient information system if possible, or
through contacting the general practitioner and other
hospitals. In case of a total nonresponse, the electronic
hospital patient information system was used as best
alternative possible for data collection on MACE. This
was done for all participants in the cohort and the date of
the last review or consultation was used to calculate
clinical follow-up time.
Major adverse cardiovascular events
MACE was defined as the composite endpoint of MI,
angina (stable and unstable), coronary revascularisation
(both percutaneous coronary intervention or coronary
artery bypass graft) or cerebrovascular accident (CVA)
at 1-year follow-up, all for which hospital admission was
required.1
Health-related quality of life
The primary endpoint of the current study was HRQoL
at 1-year follow-up. For the assessment of HRQoL, the
(validated) Dutch version of the EQ-5D-5L was used and
was sent out 1 year after surgery.8 The EQ-5D-5L is a
PROM widely used around the world.17 It covers five
domains (mobility, self-care, usual activities, pain/dis-
comfort, anxiety/depression) and each domain has five
answer categories (no problems to severe problems).
HRQoL total score was calculated from the five dimen-
sions of the EQ-5D-5L, with a standard set of population-
based weights validated for the Netherlands.8 Calculated
index scores range from 1 (best health state) to0.446 for
the worst health state possible, with negative scores
reflecting a health state worse than death. A mean differ-
ence of 0.037 to 0.069 in EQ-5D-5L is considered clini-
cally relevant.18 Additionally, the EuroQol visual
analogue scale (EQ-VAS) score was assessed. The EQ
VAS records the patient’s overall current state of health
on a vertical visual analogue scale, where the endpoints
are labelled from 100 (the best health you can imagine) to
0 (the worst health you can imagine). The EQ VAS
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provides a quantitative measure of the patient’s percep-
tion of their overall state of health.
Statistical analysis
Descriptive statistics are presented as numbers (%).
Continuous data are given as median [IQR]. Baseline
characteristics were stratified by troponin categories and
compared using Pearson’s x2 analyses or Fisher’s exact
test for categorical data, and the Kruskal–Wallis test for
continuous data. The Kernel density estimation plot was
used to visualise the distribution of HRQoL total scores
per troponin category. Sensitivity analysis was performed
to compare baseline characteristics between responders
and nonresponders to the questionnaire. To investigate
the influence of troponin concentrations higher than the
reference category (i.e. values <14 ng l1) on HRQoL
total score, Tobit regression was performed and right-
censored at 1. This censoring was performed because of
skewed data on the one hand and a maximum perfor-
mance limit of 1 on the other; a defined boundary which
can be silently exceeded by individual performance.19,20
Regression coefficients are presented along with their
95% confidence interval (CI). Multivariable analysis
included all baseline characteristics [sex, age, coronary
heart disease, diabetes, CVA, chronic obstructive pulmo-
nary disease (COPD), renal failure, peripheral arterial
disease (PAD), chronic heart failure, type of surgery and
emergency surgery], as the model was not limited by the
number of confounding factors. Sensitivity analysis was
performed to assess the effect of MACE on patient-
reported HRQoL total score. For all tests, a probability
value for significance of less than 0.05 (two-sided) was
used. All statistical analyses were performed with SPSS
statistical software, version 24 (SPSS Inc., Chicago, Illi-
nois, USA) or R Statistical Software, version 1.0.153 (Free
Software Foundation Inc., Boston, MA, USA) for Kernel
Density Plot, Tobit Regression21 and Likert-Scale Plot.22
Results
Study population
From the 1st July 2012 to the 1st 2015, 3085 consecutive
patients with postoperative troponin measurements were
enrolled. Within the first year 451 (14.6%) patients died,
leaving 2634 patients eligible for study (Fig. 1). Of these,
1297 (49.2%) returned a completed questionnaire on
quality of life at a median follow-up duration of 1.3
[1.2 to 1.6] years after surgery. The response rate between
patients with and without troponin elevation was 49.5 vs.
50.3%, respectively. In the nonresponders, histories of
CVA (17.3 vs. 14.3%, P¼ 0.03), COPD (16.4 vs. 11.5%,
P< 0.001) and diabetes mellitus (27.5 vs. 19.8%,
P< 0.001) were more frequent when compared with
the responders. The incidence of MACE did not differ
between responders and nonresponders (5.0 vs. 5.4%,
P¼ 0.67) at 1-year follow-up.
Overall, in the final study sample the median age was 69
[64 to 74] years and male sex was predominant (60.1%)
(Table 1). A history of cardiovascular diseases and sub-
sequent medical therapy was more frequently observed
in higher categories of postoperative troponin release.
With increasing levels of peak troponin concentrations,
time to discharge was prolonged and fewer people were
discharged home (Table 1). In 105 (8.1%) patients with
postoperative troponin measurements at least 50 ng l1,
23 (21.9%) could be classified as postoperative MI.
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Fig. 1
No troponin
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Health-related quality of life
Overall, the median score for HRQoL using the EQ-5D-
5L was 0.82 [0.68 to 0.91] and 80 [65 to 90] for the EQ-
VAS score, 1 year postoperatively. A shift towards lower
HRQoL scores for higher troponin category was observed
(Table 2, Fig. 2, Appendix A, http://links.lww.com/EJA/
A317). For patients with values less than 14 ng l1, the
majority reported no problems in all domains except for
pain and/or discomfort (Fig. 3). In this domain, the
severity of reported symptoms was increased and this
was seen across all troponin categories. Increase in sever-
ity of the symptom reported for other domains accrued
stepwise with increasing troponin categories. For the 65
patients experiencing MACE during follow-up, median
HRQoL total score was 0.77 [0.63 to 0.85] compared with
0.82 [0.69 to 0.92] for patients without MACE
(P¼ 0.004). The same trend was observed for the EQ-
VAS score; median 70 [50 to 80] compared with 80 [65 to
90] (P¼ 0.025) for patients with and without MACE,
respectively (Table 2).
For HRQoL, Tobit regression analysis revealed a signifi-
cant stepwise impairment for HRQoL with b0.07 (95%
CI 0.10 to 0.04), 0.13 (95% CI 0.20 to 0.06) and
0.19 (95% CI 0.30 to 0.07) for increasing troponin
category, respectively (Table 3). When adjusted for the
previous medical history, results were b 0.06 (0.09 to
0.02),0.11 (0.18 to 0.04) and0.18 (0.29 to 0.07) per
increasing troponin category, respectively (Table 3).
Other independent predictors for lower HRQoL were
COPD, female sex, PAD and increasing age. Sensitivity
analyses in patient without MACE revealed similar b
for impairment.
Discussion
In this study, we analysed the association between post-
operative troponin release and self-reported HRQoL at 1-
year follow-up in patients who underwent intermediate-
to-high risk noncardiac surgery. Our results demonstrate
that increased troponin levels are independently associ-
ated with HRQoL and that there is an inverse association
between categories of troponin concentration and
reported health status 1 year after surgery.
In our study cohort with a median age of 69 years, we
found a median HRQoL total score of 0.82. For reference,
Myocardial injury and health-related quality of life 683
Table 1 Baseline characteristics stratified by troponin category
hsTnT values (ng lS1)
<14 14 to 49 50 to 149 >–150
(nU635) (nU557) (nU79) (nU26) P value
Age (years) 66 [63 to 71] 72 [66 to 77] 72 [67 to 76] 74 [66 to 76] <0.001
Sex (male) 317 (49.9) 386 (69.3) 56 (70.9) 20 (76.9) <0.001
Hypertension 299 (47.1) 322 (57.8) 51 (64.6) 16 (61.5) <0.001
Coronary artery disease 76 (12.0) 131 (23.5) 25 (31.6) 16 (61.5) <0.001
Myocardial infarction 40 (6.3) 78 (14.0) 17 (21.5) 10 (38.5) <0.001
Cerebrovascular accident 68 (10.7) 92 (16.5) 17 (21.5) 8 (30.8) <0.001
PAD 57 (9.0) 72 (12.9) 12 (15.2) 1 (3.8) 0.056
COPD 54 (8.5) 75 (13.5) 18 (22.8) 2 (7.7) <0.001
Diabetes mellitus 100 (15.7) 121 (21.7) 27 (34.2) 9 (34.6) <0.001
Current or history of heart failure 9 (1.4) 42 (7.5) 6 (7.6) 6 (23.1) <0.001
Renal failure 13 (2.0) 57 (10.2) 30 (38.0) 6 (23.1) <0.001
Medication use
Beta-blockers 184 (29.0) 239 (42.9) 40 (50.6) 15 (57.7) <0.001
Statins 237 (37.3) 288 (51.7) 41 (51.9) 18 (69.2) <0.001
ACE inhibitor 119 (18.7) 144 (25.9) 23 (29.1) 11 (42.3) 0.001
Aspirin 159 (25.0) 215 (38.6) 37 (46.8) 16 (61.5) <0.001
Oral anticoagulants 36 (5.7) 82 (14.7) 14 (17.7) 5 (19.2) <0.001
Diuretics 138 (21.7) 174 (31.2) 34 (43.0) 10 (38.5) <0.001
Insulin 29 (4.6) 45 (8.1) 17 (21.5) 6 (23.1) <0.001
Type of surgery 0.028
General 79 (12.4) 70 (12.6) 6 (7.6) 4 (15.4)
Orthopaedics 110 (17.3) 92 (16.5) 15 (19.0) 2 (7.7)
Urology/Gynaecology 138 (21.7) 85 (15.3) 10 (12.7) 2 (7.7)
Vascular 139 (21.9) 163 (29.3) 24 (30.4) 7 (26.9)
Other 169 (26.6) 147 (26.4) 24 (30.4) 11 (42.3)
Emergency surgery 19 (3.0) 23 (4.1) 17 (21.5) 8 (30.8) <0.001
Length of surgery (min) 212 [165 to 296] 201 [157 to 272] 193 [148 to 244] 200 [43 to 250] 0.029
Type of anaesthesia 0.242
General 614 (96.7) 531 (95.3) 75 (94.9) 25 (96.2)
Combined general and epidural 63 (9.9) 37 (6.6) 6 (7.6) 4 (15.4)
Spinal 15 (2.4) 23 (4.1) 2 (2.5) 0 (0.0)
Regional 50 (7.9) 42 (7.5) 6 (7.6) 0 (0.0)
Hospital admission (days) 5 [3 to 8] 7 [4 to 12] 10 [6 to 14] 12 [8 to 26] <0.001
Discharged home 593 (93.4) 487 (87.4) 62 (78.5) 20 (76.9) <0.001
ACE, angiotensin-converting-enzyme inhibitors; hsTnT, high-sensitivity troponin T. Values presented are number (proportion) or median [IQR]. Renal failure is defined as
creatinine values more than 177mmol l1. COPD, chronic obstructive pulmonary disease; PAD, peripheral arterial disease.
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the EQ-5D-5L index norm for the general population in
the Netherlands aged 60 to 70 years is set at 0.84.8 When
scores are stratified by troponin category, patients with no
elevation (i.e. the reference category of <14 ng l1) have
similar values. A decrement towards 0.71 is seen when
postoperative troponin concentrations increase. Mitchell
et al.23 investigated the relative impact of several diseases
on health status in a nonsurgical cohort. Compared with
healthy individuals, they found lower health status for
major (chronic) health conditions like heart disease,
diabetes, depression and cancer. More importantly, they
showed that in terms of disease severity, HRQoL
decreased as disease severity increased. The same trend
is seen in our results. After adjustment for previous
medical history, HRQoL total score fell with increasing
levels of troponin concentrations when compared with
values in the reference category of less than 14 ng l1.
Furthermore, relationships for known independent pre-
dictors of impaired HRQoL other than troponin, like
female sex, COPD, CVA, PAD and increasing age were
identified in our study.8,24–27
The cardiac biomarker troponin has proven its value in
the field of cardiology. Postoperative measurements are
increasingly incorporated into current clinical practice
because of their prognostic capability for both adverse
cardiovascular events and mortality following sur-
gery.1,3,28 To these we now add these clinical outcome
measures derived from the patients’ own perceptions of
health. However, how to respond clinically to elevated
troponin levels remains a topic of debate. McCarthy
et al.15 explored the differential diagnosis in nonsurgical
patients with increased troponins, with myocardial
ischaemia as the most common cause of abnormal con-
centration. It has been frequently suggested that coronary
artery disease (CAD) is attributable to myocardial oxygen
supply–demand mismatch in surgical patients.29,30 With
its increasing incidence worldwide and with the character
of a chronic disease, CAD will continue to affect physical,
psychological and social wellbeing. In ischaemic heart
disease patients, increased myocardial ischaemia leads to
a lower quality of life.26,31 In haemodialysis patients, a
similar association was observed. High troponin T levels
were independently associated with deterioration in the
physical domains of HRQoL.32 In the current study, an
increase in severity of the symptom reported domains,
also accrued stepwise with increasing troponin categories.
We have previously shown that time to MACE was
inversely related to higher troponin concentrations.1
Moreover, time to discharge was prolonged and fewer
people were discharged home. When observing baseline
684 Mol et al.
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Kernel density estimation plot of the distributions of the health-related quality-of-life total score stratified by troponin category.
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characteristics, a higher prevalence of cardiovascular
comorbidity was seen across higher concentrations. It is
likely that the occurrence of MACE has negatively
influenced HRQoL.31 However, in sensitivity analyses,
deterioration of HRQoL scores in the absence of MACE
is also observed at follow-up. Therefore, it is probable
that the degree of myocardial injury signals the severity of
underlying cardiovascular burden, which influences per-
ceived quality of life. Next to having prognostic capabili-
ties, troponin levels measured immediately after
noncardiac surgery might serve as an indicator for lower
quality of life.
There are some limitations to this study. First, we have
only a single measurement of HRQoL, preventing us
from commenting on the course of peri-operative change,
which could have added valuable information on the
quality of life after surgery. This also accounts for tropo-
nin measurements. High pre-operative troponin concen-
trations could reflect chronic cardiovascular comorbidity
and this is known to correlate with lower perceived
quality of life. On the contrary, routine pre-operative
troponin measurements were not available in the cohort
and their influence could therefore not be assessed.
Second, the literature does not provide nondisease-spe-
cific guidelines for cut-off values to make the EQ-5D-5L
Total Score manageable for daily clinical practice. We
used EQ-5D-5L as a continuous score to prevent infor-
mation loss through dichotomisation of the results (as
proposed for the EQ-5D3L). Whether the effect of
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Fig. 3
How do you feel today?
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Likert-scale plot for the five dimensions of the EuroQol five-dimensional questionnaire stratified by troponin category. The scale displays percentages
of answers for each dimension, with ‘no problems’ on the left side and ‘slight’, ‘moderate’, ‘severe’ and ‘extreme’ on the right side (with a darker
colour green reflecting more severe symptoms).
Table 2 Comparison of symptom reports on the EuroQol questionnaire stratified by troponin category
hsTnT values (ng lS1)
<14 14 to 49 50 to 149 >–150
HRQoL (nU635) (nU557) (nU79) (nU26) P value
Total score 0.85 [0.72 to 1.00] 0.81 [0.66 to 0.90] 0.77 [0.64 to 0.86] 0.71 [0.38 to 1.0] <0.001
EQ-VAS 80 [69 to 90] 75 [60 to 85] 70 [55 to 80] 63 [50 to 80] <0.001
Values are presented as median [IQR]. EQ-VAS, EuroQol visual analogue scale; HRQoL, health-related quality of life; hsTnT, high-sensitivity troponin T.
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myocardial injury on HRQoL is mediated via the devel-
opment of adverse cardiac events which cause a decrease
in HRQoL, or by the degree of myocardial damage, is
difficult to determine. The presence of cardiovascular
comorbidity is taken into account in the regression model;
however, residual confounding can still be present. Third,
an issue with working with utility values is that values are
scaled, ranging from 0.446 to 1, and thereby at risk for a
ceiling and/or floor effect.20 The distribution (stratified per
troponin category) clearly shows that the majority of
patients score between 0.75 and 1. Individuals can have
a maximum score of 1 while having different degrees of
health performance. Therefore, we performed a Tobit
regression model to assess the relationship between
HRQoL and postoperative troponin concentrations.20 As
aforementioned, utility scores are associated with some
uncertainty. The results of the current study can be dis-
torted by being subject to responder bias. When measuring
quality of life, patients are prone to self-selection bias.
When comparing baseline characteristics for prior medial
history between responders and nonresponders, the higher
incidence of comorbidities like COPD and diabetes seen
in the nonresponders could reflect a nonresponse bias
effect.33 The direction and extent of such bias is difficult
to estimate. Last, we have no information on the occur-
rence of primarily surgical complications, which could
influence the patients’ overall experience of quality of life.
Conclusion
Higher levels of postoperative troponin concentrations
measured immediately after surgery were independently
associated with lower self-reported HRQoL 1-year after
noncardiac surgery. These findings support the use of
routine peri-operative troponin measurements. Further
studies designed to improve postoperative patient-
relevant outcomes in identified high-risk patients
are indicated.
Acknowledgements relating to this article
Assistance with the study: we would like to thank S. Roubos, M.
Janssen and C. Steenweg for their assistance with the collection
of data.
Financial support and sponsorship: this work was supported by
departmental sources and Stichting Coolsingel. KHJMM is sup-
ported by an unrestricted grant from Lijf en Leven Foundation.
Conflicts of interest: none.
Presentation: content of this article was presented at the annual
meeting of the American Society of Anesthesiologists 2019.
References
1 Mol KHJM, Hoeks SE, Liem VGB, et al. Postoperative troponin release is
associated with major adverse cardiovascular events in the first year after
noncardiac surgery. Int J Cardiol 2019; 280:8–13.
2 Devereaux PJ, Chan MTV, Alonso-Coello P, et al., Vascular Events in
Noncardiac Surgery Patients Cohort Evaluation (VISION) Study
Investigators. Association between postoperative troponin levels and 30-
day mortality among patients undergoing noncardiac surgery. JAMA 2012;
307:2295–2304.
3 vanWaes JA, Nathoe HM, deGraaff JC, et al., Cardiac Health After Surgery
(CHASE) Investigators. Myocardial injury after noncardiac surgery and its
association with short-term mortality. Circulation 2013; 127:2264–2271.
4 Thygesen K, Alpert JS, Jaffe AS, et al., ESC Committee for Practice
Guidelines (CPG). Third universal definition of myocardial infarction. Eur
Heart J 2012; 33:2551–2567.
5 van Waes JA, Grobben RB, Nathoe HM, et al., Cardiac Health After
Surgery (CHASE) Investigators. One-year mortality, causes of death, and
cardiac interventions in patients with postoperative myocardial injury.
Anesth Analg 2016; 123:29–37.
686 Mol et al.
Table 3 Censored Tobit regression for health-related quality of life total score
Univariable Multivariable
HRQoL ß (95% CI) ß (95% CI)
Troponin
<14ng l1 ref ref
14 to 49ng l1 0.07 (0.10 to 0.04) 0.06 (0.09 to 0.02)
50 to 149ng l1 0.13 (0.20 to 0.06) 0.11 (0.18 to 0.04)
>150ng l1 0.19 (0.30 to 0.07) 0.18 (0.29 to 0.07)
Type of surgery
General ref ref
Orthopaedic 0.16 (0.10 to 0.21) 0.13 (0.08 to 0.19)
Urology/Gynaecology 0.19 (0.13 to 0.24) 0.15 (0.10 to 0.20)
Vascular 0.14 (1.10 to 0.19) 0.17 (0.12 to 0.22)
Other 0.07 (0.02 to 0.12) 0.05 (0.002 to 0.10)
Sex (female) 0.07 (0.11 to 0.04) 0.08 (0.11 to 0.05)
Age 0.01 (0.01 to 0.004) 0.003 (0.005 to 0.0004)
Hypertension 0.06 (0.06 to 0.06) 0.027 (0.058 to 0.005)
CAD 0.07 (1.10 to 0.04) 0.032 (0.07 to 0.01)
Cerebrovascular accident 0.09 (0.13 to 0.06) 0.07 (0.11 to 0.03)
Peripheral arterial disease 0.07 (0.10 to 0.04) 0.12 (0.17 to 0.06)
Renal failure 0.006 (0.026 to 0.039) 0.09 (0.02 to 0.15)
COPD 0.16 (0.19 to 0.12) 0.11 (0.16 to 0.07)
Diabetes 0.05 (0.08 to 0.02) 0.03 (0.06 to 0.01)
Congestive heart failure 0.07 (0.10 to 0.04) 0.001 (0.07 to 0.08)
Emergency surgery 0.03 (0.06 to 0.003) 0.01 (0.08 to 0.06)
Univariable and adjusted ß coefficients from Tobit regression of HRQoL total score. Total number of observations: 1297. The model is right-censored at 1, as this is the
maximum HRQoL total score. Total number of censored observations: 292. Regression coefficients represent the mean change in HRQoL. CAD, coronary artery disease;
CI, confidence interval; COPD, chronic obstructive pulmonary disease; HRQoL, health-related quality of life.
Eur J Anaesthesiol 2020; 37:680–687
Copyright © European Society of Anaesthesiology. Unauthorized reproduction of this article is prohibited.
6 Ekeloef S, Alamili M, Devereaux PJ, et al. Troponin elevations after non-
cardiac, non-vascular surgery are predictive of major adverse cardiac
events and mortality: a systematic review and meta-analysis. Br J Anaesth
2016; 117:559–568.
7 Black N. Patient reported outcome measures could help transform
healthcare. BMJ 2013; 346:f167.
8 Versteegh MM, Vermeulen KM, Evers SMAA, et al. Dutch tariff for the five-
level version of EQ-5D. Value Health 2016; 19:343–352.
9 EuroQol Group. EuroQol – a new facility for the measurement of health-
related quality of life. Health Policy 1990; 16:199–208.
10 Mommersteeg PMC, Denollet J, Spertus JA, et al. Health status as a risk
factor in cardiovascular disease: a systematic review of current evidence.
Am Heart J 2009; 157:208–218.
11 Liem VGB, Hoeks SE, Gru¨ne F, et al. Prognostic value of postoperative
high-sensitivity troponin T in patients with different stages of kidney disease
undergoing noncardiac surgery. Br J Anaesth 2018; 120:84–93.
12 van Lier F, Wesdorp FHIM, Liem VGB, et al. Association between
postoperative mean arterial blood pressure and myocardial injury after
noncardiac surgery. Br J Anaesth 2018; 120:77–83.
13 World Medical Association. World Medical Association declaration of
Helsinki: ethical principles for medical research involving human subjects.
JAMA 2013; 310:2191–2194.
14 von Elm E, Altman DG, Egger M, et al. Strengthening the reporting of
observational studies in epidemiology (STROBE) statement: guidelines for
reporting observational studies. BMJ 2007; 335:806–808.
15 McCarthy CP, Raber I, Chapman AR, et al. Myocardial injury in the era of
high-sensitivity cardiac troponin assays: a practical approach for clinicians.
JAMA Cardiol 2019; 4:1034–1042.
16 Giannitsis E, Kurz K, Hallermayer K, et al. Analytical validation of a high-
sensitivity cardiac troponin T assay. Clin Chem 2010; 56:254–261.
17 Devlin NJ, Brooks R. EQ-5D and the EuroQol Group: past, present and
future. Appl Health Econ Health Policy 2017; 15:127–137.
18 McClure NS, Sayah FA, Xie F, et al. Instrument-defined estimates of the
minimally important difference for EQ-5D-5L index scores. Value Health
2017; 20:644–650.
19 Twisk J, Rijmen F. Longitudinal Tobit regression: a new approach to analyze
outcome variables with floor or ceiling effects. J Clin Epidemiol 2009;
62:953–958.
20 Austin PC. A comparison of methods for analyzing health-related quality-of-
life measures. Value Health 2002; 5:329–337.
21 Henningsen A. censReg: censored regression (Tobit) models. 2017.
22 Bryer J, Speerschneider K. Likert: analysis and visualization Likert items.
2016.
23 Mitchell PM, Al-Janabi H, Richardson J, et al. The relative impacts of disease
on health status and capability wellbeing: a multi-country study. PLoS One
2015; 10:e0143590.
24 Hicken GJ, Lossing AG, Ameli fM. Assessment of generic health-related
quality of life in patients with intermittent claudication. Eur J Vasc Endovasc
Surg 2000; 20:336–341.
25 de Torres JP, Casanova C, Hernandez C, et al. Gender and COPD in
patients attending a pulmonary clinic. Chest 2005; 128:2012–2016.
26 De Smedt D, Clays E, Annemans L, et al. Health related quality of life in
coronary patients and its association with their cardiovascular risk profile:
results from the EUROASPIRE III survey. Int J Cardiol 2013; 168:898–
903.
27 Janssen B, Szende A. Self-Reported Population Health: An International
Perspective based on EQ-5D. Chapter 3 Population norms for the EQ-5D.
2014.
28 Devereaux PJ, Biccard BM, Sigamani A, et al., Writing Committee for the
VISION Study Investigators. Association of postoperative high-sensitivity
troponin levels with myocardial injury and 30-day mortality among patients
undergoing noncardiac surgery. JAMA 2017; 317:1642–1651.
29 Devereaux PJ, Duceppe E, Guyatt G, et al., MANAGE Investigators.
Dabigatran in patients with myocardial injury after noncardiac surgery
(MANAGE): an international, randomised, placebo-controlled trial. Lancet
2018; 391:2325–2334.
30 Sheth T, Chan M, Butler C, et al., Coronary Computed Tomographic
Angiography and Vascular Events in Noncardiac Surgery Patients Cohort
Evaluation Study Investigators. Prognostic capabilities of coronary
computed tomographic angiography before noncardiac surgery:
prospective cohort study. BMJ 2015; 350:h1907.
31 Tusˇek-Bunc K, Petek D. Comorbidities and characteristics of coronary
heart disease patients: their impact on health-related quality of life. Health
Qual Life Outcomes 2016; 14:159.
32 Williams CE, Curtis BM, Randell EW, et al. Cardiac biomarkers and health-
related quality of life in new hemodialysis patients without symptomatic
cardiac disease. Can J Kidney Health Dis 2014; 1:16.
33 Sedgwick P. Nonresponse bias versus response bias. BMJ 2014;
348:g2573.
Myocardial injury and health-related quality of life 687
Eur J Anaesthesiol 2020; 37:680–687
